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Xenotransplantation holds promise to solve the ever
increasing shortage of donor organs for allotransplantation.
In the last 2 decades, major progress has been made in
understanding the immunobiology of pig-into-(non)human
primate transplantation and today we are on the threshold of
the first clinical trials. Hyperacute rejection, which is mediated
by pre-existing anti-aGal xenoreactive antibodies, can in
non-human primates be overcome by complement- and/or
antibody-modifying interventions. A major step forward
was the development of genetically engineered pigs, either
transgenic for human complement regulatory proteins or
deficient in the a1,3-galactosyltranferase enzyme. However,
several other immunologic and nonimmunologic hurdles
remain. Acute vascular xenograft rejection is mediated by
humoral and cellular mechanisms. Elicited xenoreactive
antibodies play a key role. In addition to providing B cell help,
xenoreactive T cells may directly contribute to xenograft
rejection. Long-term survival of porcine kidney- and heart
xenografts in non-human primates has been obtained but
required severe T and B cell immunosuppression. Induction of
xenotolerance, e.g. through mixed hematopoietic chimerism,
may represent the preferred approach, but although proof of
principle has been delivered in rodents, induction of pig-to-
non-human primate chimerism remains problematic. Finally,
it is now clear that innate immune cells, in particular
macrophages and natural killer cells, can mediate xenograft
destruction, the determinants of which are being elucidated.
Chronic xenograft rejection is not well understood, but recent
studies indicate that non-immunological problems, such as
incompatibilities between human procoagulant and pig
anticoagulant components may play an important role. Here,
we give a comprehensive overview of the currently known
obstacles to xenografting: immune and non-immune
problems are discussed, as well as the possible strategies
that are under development to overcome these hurdles.
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The development of organ allotransplantation in the second
half of the twentieth century can be considered a landmark in
the history of medicine. Major advances in understanding
transplantation immunology, development of immuno-
suppressives, and surgical techniques have made allografting
the treatment of choice for end-stage organ failure such as
renal insufficiency. As a result of its own success, however,
allotransplantation faces, since several decades, an acute
shortage in donated human organs. Currently, there are
approximately 75 000 and 11 300 patients on the kidney
transplant waiting list in the United States and Europe,
respectively.1–3 In Europe, only 3 540 kidney transplants were
performed in 2005, with an average waiting time of 3.2 years.
The overall mortality on the waiting list is approximately 6%
per year.2,3 The use of xenogeneic cells or tissues is one of the
alternative solutions that could alleviate the gap between
organ supply and demand.
Although nonhuman primates are phylogenetically closely
related to humans, the pig is considered as the most suitable
xenograft donor. Pig organs are physically and physiologically
suited for transplantation in humans, they breed easily
without posing major ethical problems, and they can be
genetically manipulated to improve suitability of donor
organs. Here, we review the current progress toward the
development of clinical xenotransplantation, and focus on
recent findings in the pig-to-nonhuman model, as this is
considered most preclinically relevant.
Early attempts at xenografting, which date from the 1960s,
revealed that immunological barriers to xenografts far
exceeded those to allografts. In the past two decades,
intensive research into the immunobiology of xenografts
has resulted in significant insights into the principles of
xenograft immune rejection and possible strategies to
circumvent it. A major step forward was the observation
that hyperacute rejection (HAR), which is the first immune
barrier to pig-to-(non)human primate organ transplantation
and is mediated by natural anti-aGal xenoreactive antibodies,
could be controlled by removing these antibodies4 and by
depleting or inhibiting complement.5 This has led to the
development of pigs expressing transgenes for human
complement regulatory proteins6–8 and a1,3-galactosyltrans-
ferase(aGalT)-deficient pigs that do not express the aGal
xenoepitope.9 However, successful control of HAR has
equally revealed the importance of other or previously
unknown immunological and nonimmunological obstacles
to xenograft survival.
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HYPERACUTE REJECTION AND aGal XENOREACTIVE
ANTIBODIES: THE FIRST HURDLE
Rejection of xenografts entails participation of the innate
immune system with natural antibody-producing B cells,
natural killer (NK) cells, macrophages, and complement, as
well as adaptive immune responses from T and B cells
(Figure 1). In addition, it is becoming increasingly clear that
physiological incompatibilities, such as incompatibilities
between human and pig coagulation pathways, lead to
xenograft injury and contribute significantly to rejection.
The established nomenclature of the different types of
xenograft rejection includes HAR, AVR (acute vascular
rejection) and its major component acute humoral xenograft
rejection (AHXR), and chronic rejection, and refers to the
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Figure 1 | Current understanding of the principal mechanisms involved in rejection of porcine xenografts in nonhuman primate.
HAR is initiated when preexisting ‘natural’ xenoantibodies, which are primarily directed toward aGal, bind to donor endothelium.
Endothelial cells are activated, complement and coagulation systems are involved, and endothelial damage and thrombosis occur. Elicited
xenoreactive antibodies, directed both at aGal and non-aGal xenoantigens are central in the development of AHXR. In addition to the
process described for HAR, binding of xenoreactive antibodies to endothelial cells results—through binding to FcgR—in antibody-
dependent cell-mediated cytotoxicity by NK cells and macrophages. Although the precise contribution of T cells in xenograft rejection is as
yet not fully understood, it has been shown that T cells are able to recognize and attack porcine aortic endothelial cells directly, and to
respond to xenogeneic antigens through the indirect pathway (presented by recipient antigen-presenting cells). NK cells are activated on
interaction with porcine aortic endothelial cells as a result of 11 deficient inhibitory signaling through killer inhibitory receptors (KIRs) (which
fail to recognize the porcine major histocompatibility complex (MHC) swine leukocyte antigen (SLA)), 21 ligation of activating NK receptors
by porcine endothelial cell-expressed ligands, such as interaction of NKG2D with ULBP1 and interaction of NKp44 with an, as yet,
unidentified ligand. Macrophage phagocytosis is triggered when lack of autologous CD47 expression on xenogeneic endothelium fails to
sustain inhibitory signaling through SIRP-a. In addition, galectin-3 was recently identified as an activating macrophage receptor for aGal.
Finally, incompatibilities between the recipient coagulation proteins and porcine endothelial cell-associated anticoagulant components
may result in a chronic procoagulant state of the xenograft endothelium, and is thought to play a role in chronic xenograft injury.
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time course and predominant mechanism of rejection. HAR
develops within 24 h. It results from the binding of
preexisting xenoreactive antibodies to endothelial cells and
activation of the complement system, resulting in vascular
deposition of immunoglobulins and complement, endothe-
lial swelling, and microvascular thrombosis.10
Hyperacute rejection affects xenografts transplanted
between discordant species, such as pig and (non)human
primates, and represents the first barrier to porcine xenograft
survival in (non)human primates. The putative xenoanti-
bodies are predominantly directed against Gala1,3Galb1,
4GlcNAc (aGal) carbohydrate residues (Figure 1). These are
abundantly expressed on endothelial cells of non-primate
mammals and New World monkeys, but are absent in
humans, apes, and Old World monkeys as these species lack
the aGalT gene to synthesize aGal. As a result, they produce
anti-aGal antibodies early in life upon encounter of aGal-
expressing microorganisms in the gastrointestinal tract, and
it is estimated that these ‘natural anti-aGal antibodies’
constitute 1% of immunoglobulins in the circulation.
Strategies to prevent HAR target the anti-aGal natural
antibody response and/or the participation of complement
(Table 1). Removal of anti-aGal antibodies and depletion or
inhibition of complement in nonhuman primate recipients
were found to protect pig xenografts from HAR but not from
AHXR, which is mediated by returning anti-aGal or newly
elicited anti-non-aGal xenoreactive antibodies.23 Transgenic
pigs were developed expressing human complement regula-
tory proteins, for example, hDAF (human decay-accelerating
factor, CD55),6 MCP (membrane cofactor protein, CD46),7
or protectin (CD59),8 but although grafts from these donor
pigs were protected from HAR, they are not completely
protected from AHXR.24 Using a combination of CD46
transgene pig heart grafts, the a-galactosyl-polyethylene
glycol conjugate TPC, and conventional immunosuppression
in baboons, McGregor et al.25,26 have obtained a median
heart graft survival time of 75–90 days. More recently,
aGalT/ pigs were developed9 and prolonged survival of
aGalT/ porcine kidney11 and heart12 grafts has equally
been obtained. Yamada et al.11 reported xenokidney graft
survival of up to 80 days, whereas aGal-specific and non-
aGal-specific xenoantibody responses were absent and kidney
grafts did not show histological signs of rejection. This study
involved the induction of T-cell xenotolerance through
vascularized xenothymus transplantation and intense im-
munosuppression with recipient thymectomy, splenectomy,
T-cell depletion, CD154 blockade, and treatment with
MMF (mycophenolate mofetil).11 Chen et al.13 subsequently
showed that in this combination, a preclinical regimen of
immunosuppression including ATG, tacrolimus, and MMF
equally could prevent HAR of aGalT/ kidneys, but
xenografts survived for 8–16 days only, and invariably
showed signs of AHXR.
In a similar model studying aGalT/ xenoheart grafts in
baboons, Kuwaki et al.12 reported survival of xenografts of
2–6 months under a regimen including T-cell depletion,
thymic irradiation, complement depletion, anti-CD154 mAb,
and MMF. HAR was prevented but grafts ultimately failed
with signs of focal AHXR and prominent intragraft presence
of thrombotic microangiopathy.12 These observations suggest
that residual xenoimmune reactivity or a dysregulated
coagulation pathway as a result of incompatibilities between
xenogeneic coagulation systems, may contribute to xenograft
failure on the longer term.
Whereas prevention of HAR of aGalT/ pig organs was a
major step forward, these key studies also indicate that
application in humans would require the development of
clinically applicable regimens to prevent AHXR, and addi-
tional adjustments to prevent other types of xenograft injury.
ACUTE XENOGRAFT REJECTION: NEED FOR INDUCTION OF
XENOTOLERANCE?
Porcine xenografts that are protected from HAR by anti-aGal
natural antibodies are subject to a second phase of rejection
that typically occurs within days, referred to as AVR
(Figure 1). Elicited xenoreactive antibodies, directed at non-
aGal xenoantigens (and aGal antigens when aGalTþ /þ organs
are used) play a major role, in concert with activated
complement and coagulation systems (AHXR).27 The patho-
Table 1 | Different approaches to overcome xenograft
rejection
Intervention Effect
Removal of anti-aGal antibodies Prevention of HAR4
Inhibition of complement
system
Prevention of HAR5
CD55, CD46, and CD59
transgenic pigs
Prevention of HAR6–8
aGalT/ pigs Prevention of HAR 11,12
Prevention of AHXR mediated by newly
elicited aGal antibodies13
Attenuated T-cell responsesa
Attenuated macrophage responses14
HLA-E transgenic pigs Prevention of NK-mediated
xenorejection15
ULBP1 transgenic pigs Prevention of NK-mediated
xenorejection16
huCD47 transgenic pigs Attenuation of macrophage
responses17
huCD39 transgenic pigs Prevention of thrombosis18
T/B-cell suppression Attenuation of T- and/or B-cell
responses
Mixed chimerism T-cell tolerance19
B-cell tolerance19
NK hyporesponsiveness20
Xenothymus transplantation T-cell tolerance21,22
AHXR, acute humoral xenograft rejection; aGalT, a1,3-galactosyltransferase; HAR,
hyperacute rejection; HLA, human leukocyte antigen; NK, natural killer.
aLin YJ, Hara H, Tai H-C et al. Xenotransplantation 2007; 14: 460.
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logical signature of AVR resembles that of HAR, but usually
includes infiltration by innate immune cells such as NK cells,
macrophages, and neutrophils,10 and their role is discussed
below. Although xenoreactive T cells are well known to
contribute to solid organ xenograft rejection by participating
in the T-cell-dependent elicited B-cell antibody response to aGal
and non-aGal xenoantigens, the direct contribution of
T cells to solid organ xenograft rejection is not well under-
stood. Attempts to overcome HAR and AHXR in nonhuman
primate studies so far have included profound T-cell suppression
and/or T-cell tolerance induction. Under these regimens, not only
T-cell help for B-cell responses is impaired, but also infiltration of
T cells in rejected grafts is not seen (Table 1).11–13 Davila et al.28
recently showed, however, that pig hearts, protected from HAR in
B-cell-depleted baboons were subject to direct injury by porcine
aortic endothelial cell-specific CD4 and CD8 T cells. Porcine
islets—in contrast to solid organ xenografts—are rejected
through predominantly cellular mechanisms involving T cells
and macrophages; aGal is poorly expressed on pig islet endocrine
cells, and pig endothelial cell survival in culture is very low,
rendering islet xenografts poorly susceptible to HAR and AHXR.
Rather, rejected pig islets are characterized by marked infiltration
with CD4 and CD8 T cells.29,30
Ohdan et al.31 demonstrated that B1b-like B cells are
responsible for natural antibody production against the well-
characterized xenoantigen aGal. The nature of non-aGal
antigens, and the characteristics of non-aGal xenoreactive
T- and B-cell responses are less well understood and are
under study. Studies on sera from baboons that rejected
xenografts indicate that anti-non-aGal xenoreactive anti-
bodies comprise a limited repertoire of antigen specificity.
Chen et al.13 demonstrated a predominant antibody response
against a 47-kDa protein, and Byrne et al. found that
antibody responses were mainly directed against extracellular
stress response and inflammation-related proteins, as well
as a number of intracellular antigens (Byrne G et al.
Xenotransplantation 2007; 14: 432). Li et al.32 recently
demonstrated that the T-cell-independent xenoantibody
response in a concordant xenogeneic combination is
exclusively mediated by marginal zone B cells. This B-cell
population is well known for producing antibody responses
against blood-borne T-independent type II antigens such as
capsular polysaccharide antigens, and xenoantigens involved
in this model are thought to have a related carbohydrate
structure. However, the data also indicated that other types of
xenoantigens may involve other B-cell populations, in
particular in T-cell-sufficient recipients where T-cell-depen-
dent help in antibody responses becomes important.32
In vitro studies have shown that activation of human
T cells by porcine endothelial cells is more vigorous than
that elicited by allogeneic cells.33,34 A very recent finding is
that the human T-cell responses toward aGalT/ cells may
be less pronounced than toward wild-type cells (Lin YJ et al.
Xenotransplantation 2007; 14: 460), suggesting that aGalT/
pig organs may provide additional advantages with regard to
cellular xenoimmune response. Interestingly, Porter et al.35
recently showed that human CD4þCD25þ regulatory
T cells can suppress in vitro CD4þ T-cell-mediated
antiporcine xenogeneic responses.
From the three key nonhuman primate studies, it is clear
that AVR can be prevented on the condition that severe
T- and B-cell depletion and/or suppression is provided.11–13
Understanding of the characteristics of the T- and B-cell
xenoresponse will aid to further refine immunosuppressive
strategies, or rather to provide a basis for the induction of
xenotolerance. The risk for treatment-related mortality with
the regimens used in these studies would indeed be
substantial. Co-stimulatory blockade with anti-CD154
monoclonal antibody, in particular, is very effective in
nonhuman primate models,36 but unfortunately is associated
with thrombotic complications making clinical applicability
problematic. Induction of B- and T-cell tolerance would
provide a reliable basis for long-term xenograft survival and
may represent the preferred approach. It has been shown in
various experimental models that transplantation of donor
thymus tissue can confer T-cell allo- and xenotolerance.37
Adequate vascularization of pig thymus grafts is a crucial
determinant, and in the pig-to-nonhuman primate combina-
tion techniques such as thymokidney or vascularized thymic
lobe transplantation, it has been shown to mediate robust
T-cell xenotolerance.11 In contrast, induction of mixed
hematopoietic chimerism by stem cell transplantation has
been shown in experimental models of allotransplantation to
provide robust T- and B-cell transplantation tolerance and
these observations in experimental models have provided the
rationale for clinical induction of allograft tolerance using
hematopoietic stem cell grafts.38 In a rodent xenogeneic
combination involving transplantation of aGalTþ /þ rat
bone marrow cells to aGalT/ mice, mixed chimerism could
be obtained and resulted in prevention of HAR, AHXR, and
cellular rejection of cardiac xenografts.39 However, persistent
mixed chimerism in pig-to-nonhuman primate combination
has so far not been obtained, and failure of engraftment is
thought to be due to immunologic as well as non-
immunologic (for example, of growth factors and adhesion
molecules) incompatibilities.40 The group of M Sykes has
demonstrated in a porcine cytokine transgenic humanized
NOD/SCID mouse model that mixed porcine–human
chimerism can establish human T-cell tolerance to porcine
antigens.41
XENOGRAFT REJECTION BY THE INNATE IMMUNE SYSTEM
Innate xenoimmune reactivity may compromise xenograft
survival even in the presence of adequate T- and B-cell
suppression or xenotolerance (Figure 1). NK cells have been
implicated in xenograft injury in rodent and pig-to-nonhu-
man primate models.42,43 Activation of NK cells involves
cytokine production and/or direct or antibody-dependent
cytotoxic lysis, and is the result of a balanced signaling
through inhibiting and activating receptors. According to the
missing self-principle, swine leukocyte antigen major histo-
compatibility complex molecules on pig endothelial cells fail
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to establish inhibition of NK cells through the killer
inhibitory receptors. Transgenic expression of human
leukocyte antigen (HLA), in particular the monomorphic
HLA-E, which is the ligand for the NK receptor CD94/
NKG2A, in HLA-E/b2microglobulin transgene pig endothe-
lial cells can effectively provide protection from in vitro
NK-mediated cytotoxic lysis.15 In contrast, cytotoxic lysis of
porcine endothelial cells by human NK cells is also dependent
on interaction with activating NK receptors, such as NKG2D
which interacts with porcine ULBP-1, and NKp44, the
porcine ligand of which is still unknown.16,44 Although non-
endothelial cells may express additional activating NK cell
ligands, the generation of pigs that are deficient in porcine
ULBP-1 but express the transgene for HLA-E/b2microglo-
bulin would represent a possible approach to prevent NK
cell-mediated rejection of xenografts (Seebach J. Xenotrans-
plantation 2007; 14: 396). NK cells may contribute to
xenograft injury through mechanisms other than cytotoxic
lysis. Very recent data indicate that transgene expression of
HLA-E/b2microglobulin by porcine endothelial cells can
equally suppress human NK cell-mediated IFN-g secretion
(Imbach L et al. Xenotransplantation 2007; 14: 404). Li et al.32
recently showed in a concordant model of xenoheart grafting
that T-independent xenoantibody production by marginal
zone B cells requires a critical help signal from NK cells,
which involved CD40–CD40L signaling. The favorable results
obtained with CD40L-blocking antibodies in nonhuman
primates may therefore also relate to effects at the level of NK
cells.12,11 Of note, whereas mixed chimerism can confer
donor-specific T- and B-cell xenotolerance, recent data in a
rat-to-mouse xenogeneic model indicate that loss of NK cell
xenoreactivity through this approach is part of a general NK
cell hyporesponsiveness.20
Macrophages have equally been implicated in the rejection
of xenogeneic solid organ or cellular grafts (Figure 1).45,46
Macrophage xenoreactivity can result from the activation by
xenoreactive T cells, which plays a role in rejection of porcine
islet xenografts,47 or from the direct interaction with inhibitory
or stimulatory macrophage receptors. SIRP-a (signal-regula-
tory protein-a) is an inhibitory receptor of macrophages, and
ligation by CD47—which is ubiquitously expressed and is
recognized as a marker of self—prevents phagocytosis of
autologous cells.48 However, interspecies incompatibility of
porcine and human or mouse CD47 leads to phagocytosis of
pig cells by human and mouse macrophages, and porcine bone
marrow cells are rapidly cleared in mice and baboons.49,17 The
recent observations that forced expression of mouse and
human CD47 in porcine cells significantly attenuates phago-
cytosis by mouse and human xenogeneic macrophages,
respectively, indicates that further genetic manipulation of
donor pigs for the expression of recipient CD47 may overcome
macrophage-mediated xenograft rejection.49,17 In addition to
their inability to mediate SIRP-a inhibition of macrophages,
porcine xenogeneic cells may actively stimulate macrophages;
Jin et al.14 recently showed that the human monocyte receptor
galectin-3 interacts with aGal.
NON-IMMUNE XENOINCOMPATIBILITIES AND ROLE IN
CHRONIC XENOGRAFT INJURY
Chronic rejection of allografts is the result of not only
immunologic but also non-immunologic mechanisms that
are in large part related to the effects of chronic immuno-
suppressive treatment (Figure 1). The phenomenon of
chronic rejection of xenografts is not well known, and this
is largely due to the difficulties in overcoming acute forms of
rejection. In the study by Kuwaki et al.,12 aGalT/ pig heart
xenografts that survived long term but eventually failed were
characterized predominantly by the presence of thrombotic
microangiopathy. Microvascular thrombosis is also a critical
feature in antibody-dependent processes of acute rejection;
ischemia-reperfusion injury and binding of xenoantibodies
to the graft endothelium result in activation of endothelial
cells and the disruption of the mechanisms that maintain
a protective anticoagulant/procoagulant balance of the
endothelial surface.50 It is as yet undetermined whether
the chronic type of rejection seen with the aGalT/ hearts is
due to low-grade residual immune reactivity such as
T-independent xenoantibody production, or rather to
immune-reactivity-independent inappropriate activation of
the coagulation pathway (Sachs DH. Xenotransplantation
2007; 14: 377). The latter may be the result of molecular
incompatibilities between pig and (non)human primate
coagulation factors (reviewed in Cowan50 and Shrivastava
et al.51). In contrast, studies by McGregor et al.52,53 in
baboons receiving CD46 transgenic pig heart grafts in
combination with TPC indicate that improved immunosup-
pression, rather than anticoagulation extends heart xenograft
survival. It is established that porcine thrombomodulin is a
poor activator of human protein C, and evidence suggests
that porcine TFPI (tissue factor pathway inhibitor) does not
bind to human factor XA.50 Findings in rodent models
indicate that forced expression of human coagulation
regulator proteins at the endothelial surface of pig organs
may be a reliable approach to create a protective environment
against (low-level) endothelium activation.50 Chen et al.54
showed that hearts from mice, genetically engineered to
express human TFPI in activated endothelial cells, were
completely protected from AHXR in T-cell-suppressed rat
recipients. CD39 is a critical thromboregulatory molecule
and transgenic expression of human CD39 in mice has been
shown to confer protection against thrombosis in cardiac
allografts and in islets perfused with human blood.18,55 CD39
transgenic pigs have been generated and show no overt
spontaneous bleeding tendency,56 and, very recently, aGalT/
pigs expressing human CD39 have been developed (Salvaris E
et al. Xenotransplantation 2007; 14: 417–418).
Additional differences in physiological systems between
pigs and humans have been identified (reviewed in Ibrahim
et al.57), but the significance of these incompatibilities in
life-supporting pig-into-human organ grafting is as yet
incompletely understood. In humans, the body temperature
is lower, red blood cell diameter is smaller and blood
viscosity is lower than in pigs, and incompatibility of the
18 Kidney International (2008) 74, 14–21
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renin–angiotensin–aldosterone system has been demons-
trated. Studies in nonhuman primates carrying life-support-
ing pig kidney xenografts have shown that fluid, acid–base,
and electrolyte balances can be maintained, but disturbances
in calcium/phosphorus balance and potassium levels have
been documented, as well as profound anemia, suggesting
that primate hematopoietic precursor cells are unresponsive
to pig erythropoietin.
SAFETY AND ETHICAL CONCERNS
A major concern with regard to the safety of xenotransplanta-
tion is the risk of cross-species transmission of porcine
pathogens to the xenograft recipient and to the community at
large. This eventuality and the inevitable requirement for
recipient and close contacts to undergo lifelong monitoring
are the basis of one of the major ethical issues surrounding
xenotransplantation.
The observations that porcine endogeneous retroviruses
(PERVs) can infect human cell lines and primary cell cultures
have raised particular concern.58 However, until today there
is no formal evidence from nonhuman primates or from
humans transplanted with pig tissue that PERV can infect
human cells in vivo.59 The biology and molecular basis of
PERV transmission to human cells are under study. Three
types of PERV have been described (PERV-A, PERV-B, and
PERV-C) and it has been shown that human-tropic PERVs
are often recombinants of PERV-A and PERV-C sequences.59
Also, selected swine exhibit the particular inability to
transmit PERV to human cells in vitro.60 Careful selection
and/or genetic engineering of pig herds should aid in
minimizing the risk for PERV infection and/or pathogenicity.
Of note, PERVs have been reported to be susceptible to
currently used antivirals.59 A recent report described a small
interfering RNA that can suppress PERV RNA expression,
and this approach may offer the additional advantage of
targeting PERV that has undergone recombination with a
human viral pathogen (Ramsoondar J et al. Xenotransplanta-
tion 2007; 14: 400). Clearly, the clinical application of
xenotransplantation will raise other important ethical issues,
and the Council of the International Xenotransplantation
Association has recently published a positional paper
addressing this issue.61
CONCLUSION: IMMINENT CLINICAL APPLICATIONS
In the last two decades, major progress has been made in the
understanding of xenoimmunobiology, and, today, we are on
the threshold of the first clinical trials. The first studies
demonstrating long-term survival of GalT/ pig organs in
nonhuman primates have provided proof of principle that
HAR can be overcome and raise hopes that remaining
immune barriers may equally be controlled. This will require
fine-tuning of T- and B-cell immunosuppressive and
tolerance-inducing strategies to clinically applicable regi-
mens. Particularly promising is the mixed chimerism
approach toward xenotolerance. Although it seems that
long-term hematopoietic chimerism is difficult to achieve in
xenogeneic combinations, human allograft studies indicate
that transient donor chimerism can be sufficient to permit
long-term allograft survival.38 Specific challenges are residual
innate immune reactivity and inappropriate activation of the
coagulation system. Critical determinants of these mechan-
isms of xenograft injury have been elucidated, and progress in
genetical engineering of pigs will allow for the development
of aGalT/ pigs that express transgenes for molecules now
believed to be important in xenograft destruction, for
example, CD39, TFPI, CD46, DAF, CD59, HLA-E, ULBP-1,
and CD47.
Hering et al. and Cardona et al.29,62 recently reported that
intraportal transplantation of adult or neonatal pig islets in
nonhuman primates, using costimulation blockade and
immunosuppression including sirolimus or everolimus,
resulted in glucose control for more than 100 days. These
studies have provided the rationale for clinical trials of
porcine islet transplantation in human diabetic patients. In
June 2007, the Alliance for Xenotransplantation in Diabetes
was established and clinical trials are being planned, provided
issues of safety, and FDA approval have been met (Rajotte RV.
Xenotransplantation 2007; 14: 446).
A rationale exists to use pig heart xenografting as a
bridging method to alloheart transplantation, and this may
become the first clinical application of solid organ xenograft-
ing (Cooper DK. Xenotransplantation 2007; 14: 379). The
prolonged use of cardiac assist devices provokes anti-HLA
antibodies frequently precluding subsequent allotransplanta-
tion. Using pig heart as ‘bridging’ approach would prevent
this risk as anti-pig xenoantibodies have been shown not to
cross-react with human HLA antigens. This approach may be
particularly relevant in neonates in need of a transplant;
neonates exhibit low immunoreactivity against ABO blood
group antigens, which exhibit strong similarities with
carbohydrate-type xenoantigens.
Xenotransplantation practices in humans have been
ongoing in several countries, mainly involving porcine islets
transplantation for diabetes.63 However, scientific organiza-
tions such as the International Xenotransplantation Associa-
tion and regulatory authorities such as the Council of
Europe, and the WHO collectively recommend that all
xenotransplant practices are reported, and that any such
future activity should take place within a national and
international regulatory framework.64 An international
inventory of xenotransplantation activities was drawn up,
and can be consulted and complemented online (Sgroi A
et al. Xenotransplantation 2007; 14: 401). Close monitoring of
xenotransplantation clinical applications should not only
safeguard principles of safety and ethical correctness, but will
also prove beneficial for the scientific development of
xenotransplantation.
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